Remix Therapeutics Closes $70 Million Series B Financing

Supports Novel Small Molecule Therapeutic Approach Designed to Reprogram RNA Processing and Modulate Gene Expression CAMBRIDGE, Mass., May 17, 2022 -- (Healthcare Sales & Marketing Network) -- Remix Therapeutics (Remix), a biotechnology company develop... Biopharmaceuticals, Venture Capital Remix Therapeutics
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news